Forte Biosciences, Inc. - 10-Q Filing
Forte Biosciences filed its Q1 2026 10-Q report showing a net loss of $22.1 million compared to $15.7 million in the same period last year, driven by increased research and development expenses rising from $12.5 million to $20.3 million.
Tickers: $FBRX